Korro Bio

Korro Bio ROCE

The Return on Capital Employed (ROCE) of Korro Bio (KRRO) as of Oct 27, 2026 is -169.80 %. In the previous year, Return on Capital Employed (ROCE) was -57.30 % — a change of 196.36% (lower).

ROCE

-169.80 %

YoY

196.36%

Last updated:

In 2025, Korro Bio's return on capital employed (ROCE) was -169.80 %, a 196.36% increase from the -57.30 % ROCE in the previous year.

The Korro Bio ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
42.56 USD
Jan 1, 2019
-12.35 USD
Jan 1, 2020
-14.31 USD
Jan 1, 2021
-27.13 USD
Jan 1, 2022
59.58 USD
Jan 1, 2023
-49.75 USD
Jan 1, 2024
-57.30 USD
Jan 1, 2025
-169.80 USD
The Korro Bio ROCE history
YEARROCEYoY
-169.80 %+196.36%
-57.30 %+15.16%
-49.75 %-183.51%
59.58 %-319.58%
-27.13 %+89.56%
-14.31 %+15.85%
-12.35 %-129.03%
42.56 %-22.63%
55.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Korro Bio Stock analysis

What does Korro Bio do? Korro Bio Inc generates revenue through the development and commercialization of genetic medicines based on RNA editing. The company's OPERA platform enables precise, transient single base edits in RNA, targeting diseases in the liver and central nervous system. Its portfolio includes programs designed to harness natural RNA editing processes without permanently altering DNA, focusing on rare and prevalent conditions. The firm's primary buyers are pharmaceutical and biotechnology companies seeking innovative therapeutic solutions. The company's business model centers on creating differentiated genetic medicine programs using its OPERA technology. By editing RNA instead of DNA, Korro Bio expands the potential applications of genetic therapies, addressing both rare and common diseases. The firm's focus on the liver and central nervous system represents key therapeutic segments for its RNA editing approach. Korro Bio's products are developed for commercialization, with revenue expected from licensing agreements and future product sales. Korro Bio Inc operates as a biopharmaceutical company with a focus on RNA editing technology. The company's proprietary OPERA platform is designed to edit RNA in vivo through synthetic oligonucleotide guides, allowing for precise modifications to protein sequences. This approach avoids permanent genome changes, making it suitable for a broader range of diseases. The company's target segments include liver and central nervous system disorders, where RNA editing offers therapeutic advantages over traditional genetic approaches. Korro Bio is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Korro Bio's Return on Capital Employed (ROCE)

Korro Bio's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Korro Bio's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Korro Bio's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Korro Bio’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Korro Bio stock

Return on Capital Employed (ROCE) of Korro Bio is -169.80 % in 2025.

Return on Capital Employed (ROCE) of Korro Bio changed from -57.30 % to -169.80 %, representing a 196.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Korro Bio since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Korro Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Korro Bio

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Korro Bio